Ligand Pharma (LGND) outperforms via a high-margin royalty model and disciplined investing. Click here to read my most recent ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Ligand Pharmaceuticals (LGND) and Illumina (ILMN). But which of these two stocks is more ...

As of September 25, 2024, the average one-year price target for Ligand Pharmaceuticals is $126.48/share. The forecasts range from a low of $111.10 to a high of $151.20. The average price target ...

The fair value estimate for Ligand Pharmaceuticals has been nudged higher, moving from US$243.44 to US$244.56 in the latest analyst update. That shift is closely tied to refreshed views on QTORIN and ...

Ligand Pharmaceuticals (LGND) stock jumps premarket as BofA starts its coverage with a Buy rating and a $244 target, citing ...

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return ...

Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc LGND, citing the distinctive ...

LGND AI Inc. has raised $9 million in funding to enhance its namesake cloud platform, which helps artificial intelligence models process satellite images. The startup announced the seed round on ...

Bumbershoot Holdings LP, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here. Bumbershoot Holdings L.P. generated a positive gross ...